Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial

Srinivasan, Sathish

doi:10.1136/bmjophth-2019-000322

Cited by 13 publications

(15 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Intraocular pressure remained practically unchanged in these studies. 11,15,24 Not even a transient increase in IOP was observed in this study; however, such changes have been reported in connection with the Sulcoflex Trifocal 703F supplementary IOL (Rayner Intraocular Lenses Ltd; Worthing, UK). 25 The convexconcave geometry, along with the four flexible loop haptics ensure enough space in the sulcus.…”

Section: Discussionmentioning

confidence: 44%

“…No complications were observed during surgery or in the postoperative period, which is a finding similar to previous studies involving the same ciliary sulcus lens family. 10,11,14,15,24 The design of the tested lenses supports the integrity and physiologic function of the anterior segment of the eye. Intraocular pressure remained practically unchanged in these studies.…”

Section: Discussionmentioning

confidence: 86%

See 1 more Smart Citation

<p>Spectacle Independence for Pseudophakic Patients – Experience with a Trifocal Supplementary Add-on Intraocular Lens</p>

Palomino-Bautista¹,

Sánchez-Jean²,

González³

et al. 2020

OPTH

View full text Add to dashboard Cite

Purpose: To evaluate the refractive and functional outcomes of the trifocal 1stQ AddOn ® (Medicontur) supplementary intraocular lenses (IOLs) designed for implantation into the ciliary sulcus. Patients and Methods: The study included 18 eyes of 11 pseudophakic patients with uncomplicated previous implantation of monofocal capsular bag IOLs. These patients had a desire for spectacle independence. Distance, intermediate and near visual acuities were measured, and defocus curves were plotted over a period of 6 months following implantation of the add-on IOLs. Intraocular pressure (IOP), endothelial cell density measurements and biomicroscopic evaluation were also performed. Results: In this study, 83.3% of eyes had spherical refractions within ±0.5 D from emetropia and 100% of eyes had spherical equivalent refractions that were within ±1.0 D of the target refraction. Visual acuities and defocus curves clearly confirmed trifocal optical performance (UDVA=0.03 ±0.05; UIVA=0.21 ±0.04; UNVA=0.12 ±0.04 logMAR; expressed as mean ±SD). Depth of focus showed identical results (DOF=0.486 D) compared to a trifocal capsular bag IOL, while the defocus curve was found to be superior in the intermediate and near ranges when compared to a trifocal capsular bag IOL. All patients achieved spectacle independence at all distances. All add-on IOLs were well positioned in the ciliary sulcus. No negative changes were noted in connection with endothelial cell counts, IOPs, the angle structure during surgery and during the follow-up period. Conclusion: The supplementary trifocal add-on IOL seems to be a safe, efficient and stable solution for achieving spectacle independence in pseudophakic patients with monofocal primary IOLs.

show abstract

Section: Discussionmentioning

confidence: 44%

Section: Discussionmentioning

confidence: 86%

<p>Spectacle Independence for Pseudophakic Patients – Experience with a Trifocal Supplementary Add-on Intraocular Lens</p>

Palomino-Bautista¹,

Sánchez-Jean²,

González³

et al. 2020

OPTH

View full text Add to dashboard Cite

show abstract

“…There (41) and provided more information about the visual and refractive outcomes. Although the SML does not offer distance magnification, it can magnify 2× for objects in a range of 10-15 cm from the eye and can be implanted through a 2.2 mm incision with a reduction of postoperative astigmatism.…”

Section: Discussionmentioning

confidence: 99%

“…There were 3 articles included in this review about SML, with 91 patients participated for follow-up from 3 to 12 months (41)(42)(43). In 2019, a prospective multicenter clinical trial done by Srinivasan reported the visual outcomes following monocular SML implantation in pseudophakia eyes with AMD (41). It includes 50 patients and a follow-up for 12 months.…”

Section: Scharioth Macular Lens (Sml)mentioning

confidence: 99%

Intraocular vision-improving devices in age-related macular degeneration

et al. 2020

View full text Add to dashboard Cite

Age-related macular degeneration (AMD) is a leading cause of blindness, especially in western countries, and will substantially burden society and the world's health care system. Patients with late AMD often accompany a progressive loss of central vision, which will heavily influence the quality of life and associated with increased risk of functional disability. The principal visual rehabilitation methods with low-vision magnifiers, such as hand or stand magnifiers, spectacles, and closed-circuit television, were cumbersome to use and cosmetically burdensome. Therefore, the development of intraocular visionimproving devices has become an attractive alternative to extraocular visual aids, and better life quality improvement has been reached among AMD patients. To evaluate each device's safety and efficacy based on current research, we searched the Cochrane Library, PubMed using pre-reported search terms and keywords combined with both Mesh term and text words. We explored randomized clinical controlled trials, cohort studies, and case serial reports and summarizes three aspects: visual outcomes, safety outcome, and quality of life outcomes. There are four types of devices recommended for AMD patients illustrating in this article: an implantable miniature telescope (IMT), IOL-VIP System, EyeMax Mono, and Scharioth macula lens (SML). There is no doubt that these technological advancements would bring new hope for AMD patients.However, the lack of randomized controls, limited follow-up duration, and various visual acuity (VA) measurements in different studies would be difficult than IOL devices.

show abstract

“…The interesting development about EyeMax Mono was to provide a high-quality image in all areas of the macular extending up to 10° from the fovea in case of preferred retina location changes or AMD progression (19). Recently, a prospective multicenter clinical trial about the Scharioth macula lens (SML) in previous pseudophakic eyes with AMD was published (20). Although the SML does not offer distance magnification, it can magnify 2× for objects in a range of 10-15 cm from the eye and can be implanted through 2.2 mm incision with a reduction of postoperative astigmatism.…”

mentioning

confidence: 99%

Recent developments in cataract surgery

Grzybowski¹

2020

Ann Transl Med

View full text Add to dashboard Cite

Recent developments in cataract surgeryAs guest editor of this special series of the Annals of Translational Medicine (ATM), I would like to share with the readers at large the contributions from invited authors who provided their unique and expert perspectives on the important and critical topics of this focus series titled "Recent Developments in Cataract Surgery".Cataract surgery is the most common surgical procedure performed in medicine. Over 20 million surgeries were carried out worldwide in the 2015, including 3.6 million in the United States of America and 4.2 million in the European Union (1). The technology progress enabled cataract surgery to become the safest and most predictable eye surgery. However, the increase in life expectancy and quality of life result in rise expectations regarding the outcomes. Presently, individuals over 70 years of age still wish to maintain an active lifestyle, including driving a car and often performing sports. Cataract surgery is no longer a procedure to eliminate the obstacle in vision providing some restoration of vision. It became a refractive procedure to eliminate all refractive errors, including astigmatism, but also in many cases managing co-existing presbyopia. Thus, this is a field of many new ideas and new developments. We still can be better and there is a demand for techniques that are even more perfect. Longer life span brings some new encounters, including more surgeries performed on patients with dementia and other comorbidities related with ageing, including glaucoma and retinal disorders. Moreover, the anticipated duration of intraocular lens (IOL) in the eye has significantly increased, thus physicochemical properties and IOL endurance should allow the IOL to keep its optical properties for up to three decades.Congenital cataract is the leading cause of preventable blindness in children (2). Early surgical intervention may prevent deprivation amblyopia and result in good visual prognosis (3). Optimal surgical management includes microincision cataract aspiration combined with posterior capsulotomy, anterior vitrectomy and primary intraocular lens (IOL) implantation (4). Primary IOL implantation is usually performed in children older than 2 years of age. IOL implantation in children younger than 2 years of age remains a matter of controversy (5). The review by Bremond-Gignac and colleagues discusses recent developments in the diagnosis and management of congenital cataract.It is well known that postoperative intraocular inflammation is usually more severe in younger children and it might be explained by an immature blood-ocular barrier and an underdeveloped immunosuppressive microenvironment or anterior chamber associated immune deviation (6,7). Proper understanding of these mechanisms is pivotal for optimal management of inflammatory response to surgical stimuli (8,9). Postoperative complications arising from intense inflammation include formation of posterior synechiae, posterior capsule opacifications, and fibrous pupillary membrane. This, reinforced...

show abstract

Implantation of Scharioth macula lens in patients with age-related macular degeneration: results of a prospective European multicentre clinical trial

Cited by 13 publications

References 25 publications

<p>Spectacle Independence for Pseudophakic Patients – Experience with a Trifocal Supplementary Add-on Intraocular Lens</p>

<p>Spectacle Independence for Pseudophakic Patients – Experience with a Trifocal Supplementary Add-on Intraocular Lens</p>

Intraocular vision-improving devices in age-related macular degeneration

Recent developments in cataract surgery

Contact Info

Product

Resources

About